{"organisms":["9031"],"publicationTypes":["Journal Article"],"abstract":"The overall mutational burden of a tumor is considered to be a predictive marker for the success of checkpoint blockade therapy. A recent study by McGranahan et al. reframes this notion by showing that clonal expression of neoantigens by tumor cells, rather than overall mutational burden, determines the response to checkpoint blockade therapy. ","title":"Tumor Heterogeneity and Tumor Immunity: A Chicken-and-Egg Problem.","pubmedId":"27166403"}